gefitinib has been researched along with Hormone-Dependent Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (88.24) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battaglia, M; Boccardo, F; Conti, G; Cruciani, G; Lapini, A; Manganelli, A; Ricci, S; Rubagotti, A | 1 |
| Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C | 1 |
| Anagnostou, VK; Dirix, LY; Gutierrez, C; Mackey, JR; Magill, P; Migliaccio, I; Neven, P; Osborne, CK; Rimm, DL; Robert, J; Schiff, R; Sellers, M; Underhill, C | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Hayes, DF | 1 |
| Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D | 1 |
| Jazieh, AR; Nahleh, ZA | 1 |
| Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G | 1 |
| Hirata, H; Iizuka, N; Inoue, R; Matsumoto, H; Matsuyama, H; Miura, K; Naito, K; Ohmi, C; Shirai, M; Yano, S | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Manzotti, M; Pelosi, G; Renne, G; Spitaleri, G | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Vankatraman, G | 1 |
| Allan, G; Campbell, MJ; Goldfine, ID; Hodges, L; Kerner, JA; Kushner, P; Maddux, BA; Shiry, L; Youngren, JF; Zavodovskaya, M | 1 |
| Almaraz-Pro, C; Colás, B; Colomer, R; Cortés, MA; López-Ruiz, P; Martín-Orozco, RM; Rodríguez-Ubreva, FJ; Ropero, S | 1 |
| Batra, SK; Depreux, P; Hauke, R; Henichart, JP; Lin, MF; Mehta, PP; Mimeault, M | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
| Barton, J; Blackledge, G; Wakeling, A | 1 |
1 review(s) available for gefitinib and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Growth factors and their receptors: new targets for prostate cancer therapy.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Gefitinib; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Trastuzumab | 2001 |
6 trial(s) available for gefitinib and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Gefitinib; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prednisone; Prognosis; Prostatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2010 |
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Treatment Outcome | 2011 |
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; England; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Treatment Outcome; Triazoles; Ultrasonography | 2005 |
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Estramustine; Gefitinib; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2006 |
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2007 |
10 other study(ies) available for gefitinib and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Tamoxifen: Dr. Jekyll and Mr. Hyde?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Trastuzumab | 2004 |
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays | 2005 |
Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Topics: Androgens; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cytochromes c; Docetaxel; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured; Veratrum Alkaloids | 2007 |
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Masoprocol; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Topics: Adenocarcinoma; Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Differentiation; Cell Line, Tumor; Culture Media, Serum-Free; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mitoxantrone; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Veratrum Alkaloids | 2007 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |